Mesothelioma Treatments Compared: Surgery, Chemo, Immunotherapy & Radiation
There are four primary treatment modalities for mesothelioma: surgery, chemotherapy, immunotherapy, and radiation therapy. Most patients receive a combination of two or more — known as multimodal therapy — because no single treatment has proven sufficient on its own. Understanding how each approach works, its typical outcomes, and its limitations helps patients and families have more informed conversations with their oncology team about the best treatment plan for their specific situation.
| Factor | Surgery | Chemotherapy | Immunotherapy | Radiation |
|---|---|---|---|---|
| How it works | Physical removal of tumors and affected tissue from the body | Cytotoxic drugs circulate systemically to kill rapidly dividing cancer cells | Checkpoint inhibitors release the "brakes" on the immune system so it can attack cancer cells | High-energy beams damage cancer cell DNA, preventing them from dividing |
| Goal | Remove all visible disease (macroscopic complete resection) | Shrink tumors, slow progression, extend survival | Enable the immune system to recognize and destroy mesothelioma cells | Kill remaining cancer cells, shrink tumors, relieve pain and symptoms |
| Common procedures/drugs | EPP or P/D (pleural); cytoreduction with HIPEC (peritoneal) | Pemetrexed + cisplatin (EMPHACIS regimen); pemetrexed + carboplatin as alternative | Nivolumab + ipilimumab (CheckMate 743); pembrolizumab in clinical trials | IMRT (intensity-modulated), SBRT (stereotactic body), palliative radiation |
| Typical duration | Single procedure (4–10 hours) plus 4–8 weeks recovery | 4–6 cycles over 12–18 weeks; each cycle is 21 days | Every 2–4 weeks for up to 2 years (or until progression/intolerance) | Daily sessions over 4–6 weeks (25–30 treatments) for curative intent; fewer for palliative |
| Side effects | Surgical risks, pain, reduced lung capacity, infection, prolonged recovery | Nausea, fatigue, anemia, low white blood cell count, kidney effects, neuropathy | Fatigue, skin rash, diarrhea, colitis, pneumonitis, thyroid dysfunction (immune-related) | Skin irritation, fatigue, esophagitis, pneumonitis, nausea (depending on treatment field) |
| Median survival improvement | 14–30 months (with multimodal therapy, depending on stage and cell type) | 12–16 months (compared to 6–9 months with supportive care alone) | 18.1 months (CheckMate 743, non-epithelioid benefit was most pronounced) | Limited survival benefit as standalone; primary role is local control and symptom relief |
| Stage eligibility | Stages I–III (select patients); not recommended for stage IV | All stages; standard first-line for inoperable patients | All stages; FDA-approved as first-line for unresectable pleural mesothelioma | All stages; used adjuvantly (after surgery) or palliatively (any stage) |
| Used as standalone? | Rarely — almost always combined with chemo and/or radiation | Yes, for patients who are not surgical candidates | Yes, as first-line treatment for unresectable disease (per FDA approval) | Yes, for palliative symptom control; rarely as sole curative intent |
| Often combined with | Neoadjuvant or adjuvant chemotherapy, radiation, and increasingly immunotherapy | Surgery (before or after), radiation, or immunotherapy | Chemotherapy (in clinical trials); being studied with surgery | Surgery (adjuvant radiation), chemotherapy |
| FDA-approved for mesothelioma? | Surgical procedures are not FDA-regulated; performed at surgeon's discretion | Pemetrexed + cisplatin approved in 2004 (based on EMPHACIS trial) | Nivolumab + ipilimumab approved October 2020 (based on CheckMate 743) | Radiation devices are FDA-cleared; specific protocols are physician-directed |
| Estimated cost range | $50,000–$150,000+ (surgical and hospital costs) | $10,000–$50,000 per cycle | $12,000–$30,000 per infusion | $10,000–$50,000 for full course |
Sources: CheckMate 743 trial (Baas et al., Lancet, 2021), EMPHACIS trial (Vogelzang et al., JCO, 2003), NCCN Clinical Practice Guidelines, National Cancer Institute, FDA approval records
Every case is different
This comparison covers general differences. Your specific situation — diagnosis type, stage, state of residence, and exposure history — determines which option delivers the most compensation.
Free & confidential · No obligation · Personalized to your situation
Key Differences
Curative vs. Palliative Intent
Surgery is the only treatment modality that can be performed with curative intent — meaning the goal is to remove all visible cancer from the body. However, even after successful surgery, microscopic disease almost always remains, which is why surgery is nearly always paired with other treatments. Chemotherapy and immunotherapy are systemic treatments that address cancer cells throughout the body but cannot eliminate bulky tumors on their own. Radiation is primarily a local treatment, excellent at killing cancer cells in a specific area but unable to address disease that has spread beyond the treatment field. Understanding this distinction helps explain why multimodal therapy is the standard of care.
The Multimodal Approach
The most favorable outcomes in mesothelioma treatment come from combining two or more modalities. A typical multimodal plan for a surgical candidate might include neoadjuvant (pre-surgery) chemotherapy to shrink tumors, followed by surgical resection, and then adjuvant radiation to the surgical site to kill remaining cells. Researchers are now studying the addition of immunotherapy to this sequence. For patients who are not surgical candidates, the combination of chemotherapy and immunotherapy — or immunotherapy alone — represents the current standard of care. Your oncology team will design a treatment plan based on your specific diagnosis, stage, cell type, and overall health.
Immunotherapy Breakthroughs: CheckMate 743
The CheckMate 743 trial represented a landmark moment in mesothelioma treatment. Published in The Lancet in 2021, this Phase III randomized trial compared nivolumab (an anti-PD-1 checkpoint inhibitor) plus ipilimumab (an anti-CTLA-4 inhibitor) against standard pemetrexed-platinum chemotherapy in 605 patients with previously untreated, unresectable malignant pleural mesothelioma. The immunotherapy combination demonstrated a median overall survival of 18.1 months versus 14.1 months for chemotherapy. The benefit was particularly pronounced in patients with non-epithelioid (sarcomatoid or biphasic) cell types, who historically had very poor responses to chemotherapy. This led to FDA approval in October 2020 — only the second systemic therapy ever approved specifically for mesothelioma after pemetrexed in 2004.
The Role of Clinical Trials
Because mesothelioma is a rare cancer with limited approved treatments, clinical trials play an especially important role. Active areas of research include combining immunotherapy with surgery, developing new targeted therapies, investigating gene therapy approaches, and testing novel drug combinations. The National Cancer Institute maintains a registry of active mesothelioma clinical trials, and major treatment centers often have trials available that are not yet broadly accessible. Patients should discuss clinical trial eligibility with their oncology team, as participation can provide access to promising new treatments while contributing to the advancement of mesothelioma care.
Which Treatment Is Right for You?
Most mesothelioma patients receive multimodal treatment — a combination of two or more approaches tailored to their specific situation. The optimal treatment plan depends on several factors.
- Surgery-based multimodal therapy may be recommended if: you have stage I–III disease, epithelioid cell type, and adequate cardiopulmonary function to tolerate surgery. This approach offers the best chance for long-term survival in eligible patients.
- Chemotherapy may be recommended if: you are not a surgical candidate, have advanced-stage disease, or need systemic treatment to control cancer progression. Pemetrexed plus cisplatin remains the standard chemotherapy regimen.
- Immunotherapy may be recommended if: you have unresectable disease, particularly with non-epithelioid cell type. The nivolumab/ipilimumab combination is now a first-line standard of care for patients who are not surgical candidates.
- Radiation may be recommended if: you need adjuvant treatment after surgery to reduce local recurrence, or palliative treatment to manage chest pain, breathing difficulty, or other symptoms at any stage.
Treatment decisions should be made with a multidisciplinary team at a center experienced in mesothelioma care. Our guide explains how to choose a mesothelioma treatment center. Ask about clinical trial options — they may provide access to emerging therapies not yet widely available. Financial compensation through lawsuits and trust funds can help cover treatment costs and support your family during this process.
- Baas P, et al. "First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial." The Lancet, 2021;397(10272):375–386
- Vogelzang NJ, et al. "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma (EMPHACIS)." Journal of Clinical Oncology, 2003;21(14):2636–2644
- NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma (Version 1.2026)
- National Cancer Institute, "Malignant Mesothelioma Treatment (PDQ) — Health Professional Version"
- U.S. Food and Drug Administration, FDA approval records for pemetrexed (2004) and nivolumab + ipilimumab for mesothelioma (2020)
Ready to Take the Next Step?
Our attorneys handle the entire process — so you can focus on what matters most. Get a free, confidential case review today.
Your information is confidential and protected by attorney-client privilege.
Call 1-800-400-1805 for immediate help.